Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

Elizabeth O’Donnell, MD, comments on how the aforementioned trials have influenced the treatment landscape for transplant-ineligible patients with newly diagnosed multiple myeloma and discusses situations in which she favors triplet therapy over quadruplet therapy for these patients.

EP: 1.Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP: 2.Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Now Viewing

EP: 3.Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP: 4.Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP: 5.Looking Ahead and Key Takeaways

EP: 6.Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP: 7.Overview of PERSEUS, IsKia, and GMMG-HD7

EP: 8.Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

1. Please comment on how the above trials influenced the treatment landscape for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma.
2. Please comment on situations in which you favor triplet therapy over quadruplet therapy for TIE patients.

Related Videos